CoChat
Sign Up
Cited by 37Nanoparticle-Based Drug DeliveryRNA Interference and Gene DeliveryAdvanced Drug Delivery Systems

Synergistic vesicle-vector systems for targeted delivery

Open access
Marquez, Christine Ardelle, Oh, Cho-Im, Ahn, Gna, Shin, Woo-Ri, Kim, Yang-Hoon, Ahn, Ji-Young·2024·Journal of Nanobiotechnology
DOI 10.1186/s12951-023-02275-6PMC PMC10763086
Open this paper in CoChat — free accountOpen PDF

Abstract

With the immense progress in drug delivery systems (DDS) and the rise of nanotechnology, challenges such as target specificity remain. The vesicle-vector system (VVS) is a delivery system that uses lipid-based vesicles as vectors for a targeted drug delivery. When modified with target-probing materials, these vesicles become powerful vectors for drug delivery with high target specificity. In this review, we discuss three general types of VVS based on different modification strategies: (1) vesicle-probes; (2) vesicle-vesicles; and (3) genetically engineered vesicles. The synthesis of each VVS type and their corresponding properties that are advantageous for targeted drug delivery, are also highlighted. The applications, challenges, and limitations of VVS are briefly examined. Finally, we share a number of insights and perspectives regarding the future of VVS as a targeted drug delivery system at the nanoscale. Graphical Abstract

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12951-023-02275-6

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Even with nanotechnology, the efficiency of targeting disease or disordered area cells with EVs is quite low.

    “To treat CNS disorders using EVs, EVs should only target the disease or disordered area cells, but even with nanotechnology, efficiency is quite low [333–336].”

    From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [334]

    The Introduction (page not provided) says nanotechnology has improved drug delivery, but delivery to a targeted location remains challenging. Clinical Applications (page not provided) also notes concerns about the target specificity of mainly unmodified EVs. Neither passage establishes that targeting efficiency is quite low for nanotechnology-enhanced EVs treating CNS disorders specifically. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 177

  1. [1]Senapati S Mahanta AK Kumar S Maiti P Controlled drug delivery vehicles for cancer treatment and their performance Sig Transduct Target Ther 2018 3 7 10.1038/s41392-017-0004-3 PMC5854578 29560283 · DOI · Paper page
  2. [2]Sabu C Rejo C Kotta S Pramod K Bioinspired and biomimetic systems for advanced drug and gene delivery J Control Release 2018 287 142 155 10.1016/j.jconrel.2018.08.033 30165138 · DOI
  3. [3]Mitchell MJ Billingsley MM Haley RM Wechsler ME Peppas NA Langer R Engineering precision nanoparticles for drug delivery Nat Rev Drug Discov 2021 20 101 124 10.1038/s41573-020-0090-8 33277608 PMC7717100 · DOI · Paper page
  4. [4]Wang K Shang F Chen D Cao T Wang X Jiao J Protein liposomes-mediated targeted acetylcholinesterase gene delivery for effective liver cancer therapy J Nanobiotechnol 2021 19 31 10.1186/s12951-021-00777-9 PMC7821407 33482834 · DOI
  5. [5]Akbarzadeh A Rezaei-Sadabady R Davaran S Joo SW Zarghami N Hanifehpour Y Liposome: classification, preparation, and applications Nanoscale Res Lett 2013 8 102 10.1186/1556-276X-8-102 23432972 PMC3599573 · DOI
  6. [6]Riaz M Riaz M Zhang X Lin C Wong K Chen X Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a review IJMS 2018 19 195 10.3390/ijms19010195 29315231 PMC5796144 · DOI
  7. [7]Mougenot MF Pereira VS Costa ALR Lancellotti M Porcionatto MA da Silveira JC Biomimetic nanovesicles—sources, design, production methods, and applications Pharmaceutics 2022 14 2008 10.3390/pharmaceutics14102008 36297442 PMC9610935 · DOI
  8. [8]Sonju JJ Dahal A Singh SS Jois SD Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment J Control Release 2021 329 624 644 10.1016/j.jconrel.2020.09.055 33010333 PMC8082750 · DOI
  9. [9]Dang XTT Kavishka JM Zhang DX Pirisinu M Le MTN Extracellular vesicles as an efficient and versatile system for drug delivery Cells 2020 9 2191 10.3390/cells9102191 33003285 PMC7600121 · DOI
  10. [10]Herrmann IK Wood MJA Fuhrmann G Extracellular vesicles as a next-generation drug delivery platform Nat Nanotechnol 2021 16 748 759 10.1038/s41565-021-00931-2 34211166 · DOI
  11. [11]Doyle L Wang M Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis Cells 2019 8 727 10.3390/cells8070727 31311206 PMC6678302 · DOI
  12. [12]Heinrich E Hartwig O Walt C Kardani A Koch M Jahromi LP Cell-derived vesicles for antibiotic delivery—understanding the challenges of a biogenic carrier system Small 2023 19 2207479 10.1002/smll.202207479 36938700 · DOI
  13. [13]O’Brien K Breyne K Ughetto S Laurent LC Breakefield XO RNA delivery by extracellular vesicles in mammalian cells and its applications Nat Rev Mol Cell Biol 2020 21 585 606 10.1038/s41580-020-0251-y 32457507 PMC7249041 · DOI · Paper page
  14. [14]Manca S Upadhyaya B Mutai E Desaulniers AT Cederberg RA White BR Milk exosomes are bioavailable and distinct microRNA cargos have unique tissue distribution patterns Sci Rep 2018 8 11321 10.1038/s41598-018-29780-1 30054561 PMC6063888 · DOI
  15. [15]Antimisiaris S Mourtas S Marazioti A Exosomes and exosome-inspired vesicles for targeted drug delivery Pharmaceutics 2018 10 218 10.3390/pharmaceutics10040218 30404188 PMC6321407 · DOI
  16. [16]Kong H Kim SB Exosomal communication between the tumor microenvironment and innate immunity and its therapeutic application Immune Netw 2022 22 e38 10.4110/in.2022.22.e38 36381957 PMC9634143 · DOI
  17. [17]Zhang Y Bi J Huang J Tang Y Du S Li P Exosome: a review of its classification, isolation techniques, storage Diagnostic Targeted Therapy Appl IJN 2020 15 6917 6934 PMC7519827 33061359
  18. [18]Munir J Lee M Ryu S Exosomes in food: health benefits and clinical relevance in diseases Adv Nutr 2020 11 687 696 10.1093/advances/nmz123 31796948 PMC7231590 · DOI
  19. [19]Ahn G Kim Y-H Ahn J-Y Multifaceted effects of milk-exosomes (Mi-Exo) as a modulator of scar-free wound healing Nanoscale Adv 2021 3 528 537 10.1039/D0NA00665C 36131751 PMC9419160 · DOI
  20. [20]Salim M Eason T Boyd BJ Opportunities for milk and milk-related systems as ‘new’ low-cost excipient drug delivery materials Adv Drug Deliv Rev 2022 183 114139 10.1016/j.addr.2022.114139 35143892 · DOI
  21. [21]Trinchese G Cavaliere G De Filippo C Aceto S Prisco M Chun JT Human milk and donkey milk, compared to cow milk, reduce inflammatory mediators and modulate glucose and lipid metabolism, acting on mitochondrial function and oleylethanolamide levels in rat skeletal muscle Front Physiol 2018 9 32 10.3389/fphys.2018.00032 29472867 PMC5810302 · DOI
  22. [22]Nemati M Singh B Mir RA Nemati M Babaei A Ahmadi M Plant-derived extracellular vesicles: a novel nanomedicine approach with advantages and challenges Cell Commun Signal 2022 20 69 10.1186/s12964-022-00889-1 35606749 PMC9128143 · DOI
  23. [23]Zhang M Xiao B Wang H Han MK Zhang Z Viennois E Edible ginger-derived nano-lipids loaded with doxorubicin as a novel drug-delivery approach for colon cancer therapy Mol Ther 2016 24 1783 1796 10.1038/mt.2016.159 27491931 PMC5112046 · DOI
  24. [24]Karamanidou T Tsouknidas A Plant-derived extracellular vesicles as therapeutic nanocarriers IJMS 2021 23 191 10.3390/ijms23010191 35008617 PMC8745116 · DOI
  25. [25]Avila-Calderón ED Ruiz-Palma MD Aguilera-Arreola MG Velázquez-Guadarrama N Ruiz EA Gomez-Lunar Z Outer membrane vesicles of gram-negative bacteria: an outlook on biogenesis Front Microbiol 2021 12 557902 10.3389/fmicb.2021.557902 33746909 PMC7969528 · DOI
  26. [26]Cecil JD Sirisaengtaksin N O’Brien-Simpson NM Krachler AM Outer membrane vesicle-host cell interactions Microbiol Spectr 2019 10.1128/microbiolspec.PSIB-0001-2018 30681067 PMC6352913 · DOI
  27. [27]Gerritzen MJH Salverda MLM Martens DE Wijffels RH Stork M Spontaneously released Neisseria meningitidis outer membrane vesicles as vaccine platform: production and purification Vaccine 2019 37 6978 6986 10.1016/j.vaccine.2019.01.076 31383485 · DOI
  28. [28]Lee E Choi D Kim K Gho YS Proteomics in gram-negative bacterial outer membrane vesicles Mass Spectrom Rev 2008 27 535 555 10.1002/mas.20175 18421767 · DOI
  29. [29]Bielaszewska M Rüter C Bauwens A Greune L Jarosch K-A Steil D Host cell interactions of outer membrane vesicle-associated virulence factors of enterohemorrhagic Escherichia coli O157: intracellular delivery, trafficking and mechanisms of cell injury PLoS Pathog 2017 13 e1006159 10.1371/journal.ppat.1006159 28158302 PMC5310930 · DOI
  30. [30]McMahon KJ Castelli ME Vescovi EG Feldman MF Biogenesis of Outer membrane vesicles in Serratia marcescens Is thermoregulated and can be induced by activation of the Rcs phosphorelay system J Bacteriol 2012 194 3241 3249 10.1128/JB.00016-12 22493021 PMC3370869 · DOI
  31. [31]Tsuji T Fujimoto T Lipids and lipid domains of the yeast vacuole Biochem Soc Trans 2018 46 1047 1054 10.1042/BST20180120 30242116 · DOI
  32. [32]Gujrati V Lee M Ko Y-J Lee S Kim D Kim H Bioengineered yeast-derived vacuoles with enhanced tissue-penetrating ability for targeted cancer therapy Proc Natl Acad Sci USA 2016 113 710 715 10.1073/pnas.1509371113 26715758 PMC4725537 · DOI
  33. [33]Cheng R Liu L Xiang Y Lu Y Deng L Zhang H Advanced liposome-loaded scaffolds for therapeutic and tissue engineering applications Biomaterials 2020 232 119706 10.1016/j.biomaterials.2019.119706 31918220 · DOI
  34. [34]Skotland T Sagini K Sandvig K Llorente A An emerging focus on lipids in extracellular vesicles Adv Drug Deliv Rev 2020 159 308 321 10.1016/j.addr.2020.03.002 32151658 · DOI
  35. [35]Bellefroid C Reusch C Lechanteur A Evrard B Debacq-Chainiaux F Mottet D Systematic study of liposomes composition towards efficient delivery of plasmid DNA as potential application of dermal fibroblasts targeting Int J Pharm 2021 593 120122 10.1016/j.ijpharm.2020.120122 33307161 · DOI
  36. [36]Naradasu D Miran W Sharma S Takenawa S Soma T Nomura N Biogenesis of outer membrane vesicles concentrates the unsaturated fatty acid of phosphatidylinositol in capnocytophaga ochracea Front Microbiol 2021 12 682685 10.3389/fmicb.2021.682685 34093510 PMC8176214 · DOI
  37. [37]Benne N Leboux RJT Glandrup M Van Duijn J Lozano Vigario F Neustrup MA Atomic force microscopy measurements of anionic liposomes reveal the effect of liposomal rigidity on antigen-specific regulatory T cell responses J Control Release 2020 318 246 255 10.1016/j.jconrel.2019.12.003 31812539 · DOI
  38. [38]Heidarli E Dadashzadeh S Haeri A State of the art of stimuli-responsive liposomes for cancer therapy Iran J Pharm Res 2017 16 1273 1304 29552041 PMC5843293
  39. [39]Kim J Li S Zhang S Wang J Plant-derived exosome-like nanoparticles and their therapeutic activities Asian J Pharm Sci 2022 17 53 69 10.1016/j.ajps.2021.05.006 35261644 PMC8888139 · DOI
  40. [40]Shin H-S Gedi V Kim J-K Lee D Detection of Gram-negative bacterial outer membrane vesicles using DNA aptamers Sci Rep 2019 9 13167 10.1038/s41598-019-49755-0 31511614 PMC6739373 · DOI
  41. [41]Liu G Kang G Wang S Huang Y Cai Q Extracellular vesicles: emerging players in plant defense against pathogens Front Plant Sci 2021 12 757925 10.3389/fpls.2021.757925 34659325 PMC8515046 · DOI
  42. [42]Manandhar SP Gharakhanian E ENV7 and YCK3, which encode vacuolar membrane protein kinases, genetically interact to impact cell fitness and vacuole morphology FEMS Yeast Res 2014 14 472 480 10.1111/1567-1364.12128 24345185 · DOI
  43. [43]De Leo V Milano F Agostiano A Catucci L Recent advancements in polymer/liposome assembly for drug delivery: from surface modifications to hybrid vesicles Polymers 2021 13 1027 10.3390/polym13071027 33810273 PMC8037206 · DOI
  44. [44]Dissanayake T Sun X Abbey L Bandara N Recent advances in lipid-protein conjugate-based delivery systems in nutraceutical, drug, and gene delivery Food Hydrocolloids for Health 2022 2 100054 10.1016/j.fhfh.2022.100054 · DOI
  45. [45]Aronson MR Medina SH Mitchell MJ Peptide functionalized liposomes for receptor targeted cancer therapy APL Bioengineering 2021 5 011501 10.1063/5.0029860 33532673 PMC7837755 · DOI
  46. [46]Muguruma K Osawa R Fukuda A Ishikawa N Fujita K Taguchi A Development of a high-affinity antibody-binding peptide for site-specific modification ChemMedChem 2021 16 1814 1821 10.1002/cmdc.202000977 33594831 · DOI
  47. [47]Tang J Wang Q Yu Q Qiu Y Mei L Wan D A stabilized retro-inverso peptide ligand of transferrin receptor for enhanced liposome-based hepatocellular carcinoma-targeted drug delivery Acta Biomater 2019 83 379 389 10.1016/j.actbio.2018.11.002 30395963 · DOI
  48. [48]Kang C, Han P, Lee JS, Lee D, Kim D. Anchor, spacer, and ligand-modified engineered exosomes for trackable targeted therapy. Bioconjugate Chem. 2020;31:2541–52. 33115231
  49. [49]Fan X Xu H Song J Jin Y Wink M Wu G Using a membrane-penetrating-peptide to anchor ligands in the liposome membrane facilitates targeted drug delivery Bioconjugate Chem 2020 31 113 122 10.1021/acs.bioconjchem.9b00798 31841319 · DOI
  50. [50]Xu W Yan X Liu N Wu G P1c peptide decorated liposome targeting αvβ3-expressing tumor cells in vitro and in vivo RSC Adv 2018 8 25575 25583 10.1039/C8RA05014G 35539761 PMC9082570 · DOI
  51. [51]Wen X Li J Cai D Yue L Wang Q Zhou L Anticancer efficacy of targeted shikonin liposomes modified with RGD in breast cancer cells Molecules 2018 23 268 10.3390/molecules23020268 29382149 PMC6017468 · DOI
  52. [52]Akbar MJ Lukasewicz Ferreira PC Giorgetti M Stokes L Morris CJ Bombesin receptor-targeted liposomes for enhanced delivery to lung cancer cells Beilstein J Nanotechnol 2019 10 2553 2562 10.3762/bjnano.10.246 31921534 PMC6941431 · DOI
  53. [53]Liang G Zhu Y Ali DJ Tian T Xu H Si K Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer J Nanobiotechnol 2020 18 10 10.1186/s12951-019-0563-2 PMC6950820 31918721 · DOI
  54. [54]Suga T Watanabe M Sugimoto Y Masuda T Kuroda N Hagimori M Synthesis of a high functionality and quality lipid with gp130 binding hydrophobic peptide for the preparation of human glioma cell-targeted PEGylated liposomes J Drug Delivery Sci Technol 2019 49 668 673 10.1016/j.jddst.2018.12.037 · DOI
  55. [56]Chen R Yuan W Zheng Y Zhu X Jin B Yang T Delivery of engineered extracellular vesicles with miR-29b editing system for muscle atrophy therapy J Nanobiotechnol 2022 20 304 10.1186/s12951-022-01508-4 PMC9235146 35761332 · DOI
  56. [57]Sasikumar PG Ramachandra M Small-molecule immune checkpoint inhibitors targeting PD-1/PD-L1 and other emerging checkpoint pathways BioDrugs 2018 32 481 497 10.1007/s40259-018-0303-4 30168070 · DOI
  57. [58]Ganesan A Ahmed M Okoye I Arutyunova E Babu D Turnbull WL Comprehensive in vitro characterization of PD-L1 small molecule inhibitors Sci Rep 2019 9 12392 10.1038/s41598-019-48826-6 31455818 PMC6712002 · DOI
  58. [59]Di J Xie F Xu Y When liposomes met antibodies: drug delivery and beyond Adv Drug Deliv Rev 2020 154–155 151 162 10.1016/j.addr.2020.09.003 32926944 · DOI
  59. [60]Yu J Hu F Zhu Q Li X Ren H Fan S PD-L1 monoclonal antibody-decorated nanoliposomes loaded with Paclitaxel and P-gp transport inhibitor for the synergistic chemotherapy against multidrug resistant gastric cancers Nanoscale Res Lett 2020 15 59 10.1186/s11671-019-3228-z 32166458 PMC7067943 · DOI
  60. [61]Kooijmans SAA Fliervoet LAL van der Meel R Fens MHAM Heijnen HFG van Bergen en Henegouwen PMP, PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time J Controll Release 2016 224 77 85 10.1016/j.jconrel.2016.01.009 26773767 · DOI
  61. [62]Guo P Yang J Jia D Moses MA Auguste DT ICAM-1-targeted, Lcn2 siRNA-encapsulating liposomes are potent anti-angiogenic agents for triple negative breast cancer Theranostics 2016 6 1 13 10.7150/thno.12167 26722369 PMC4679350 · DOI
  62. [63]Brindisi M Kessler SM Kumar V Zwergel C Editorial: multi-target directed ligands for the treatment of cancer Front Oncol 2022 12 980141 10.3389/fonc.2022.980141 35992885 PMC9389393 · DOI
  63. [64]Sekhon SS Ahn G Sekhon SS Ahn J-Y Kim Y-H Bioengineered aptamer-nanoconjugates for cancer theragnosis Mol Cell Toxicol 2018 14 361 368 10.1007/s13273-018-0040-2 · DOI
  64. [65]Shin W-R Park D-Y Kim JH Lee J-P Thai NQ Oh I-H Structure based innovative approach to analyze aptaprobe–GPC3 complexes in hepatocellular carcinoma J Nanobiotechnol 2022 20 204 10.1186/s12951-022-01391-z PMC9044640 35477501 · DOI
  65. [66]Khan AA Allemailem KS Almatroodi SA Almatroudi A Rahmani AH Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications Biotech 2020 10 163 PMC7062946 32206497
  66. [67]Moosavian SA Sahebkar A Aptamer-functionalized liposomes for targeted cancer therapy Cancer Lett 2019 448 144 154 10.1016/j.canlet.2019.01.045 30763718 · DOI
  67. [68]Almeida B Nag OK Rogers KE Delehanty JB Recent progress in bioconjugation strategies for liposome-mediated drug delivery Molecules 2020 25 5672 10.3390/molecules25235672 33271886 PMC7730700 · DOI
  68. [69]Viglasky V Hianik T Potential uses of G-quadruplex-forming aptamers GPB 2013 32 149 172 10.4149/gpb_2013019 23459572 · DOI
  69. [70]O. Tucker W, T. Shum K, A. Tanner J. G-quadruplex DNA Aptamers and their Ligands: Structure, Function and Application. CPD. 2012;18:2014–26 22376117
  70. [71]Sekhon SS Ahn G Park G-Y Park D-Y Lee S-H Ahn J-Y The role of aptamer loaded exosome complexes in the neurodegenerative diseases Toxicol Environ Health Sci 2019 11 85 93 10.1007/s13530-019-0392-6 · DOI
  71. [72]Torchilin V Antibody-modified liposomes for cancer chemotherapy Expert Opin Drug Deliv 2008 5 1003 1025 10.1517/17425247.5.9.1003 18754750 · DOI
  72. [73]Bertrand N Wu J Xu X Kamaly N Farokhzad OC Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology Adv Drug Deliv Rev 2014 66 2 25 10.1016/j.addr.2013.11.009 24270007 PMC4219254 · DOI
  73. [74]Nag O Awasthi V Surface Engineering of Liposomes for Stealth Behavior Pharmaceutics 2013 5 542 569 10.3390/pharmaceutics5040542 24300562 PMC3873679 · DOI
  74. [75]Li F Mei H Xie X Zhang H Liu J Lv T Aptamer-conjugated chitosan-anchored liposomal complexes for targeted delivery of erlotinib to EGFR-mutated lung cancer cells AAPS J 2017 19 814 826 10.1208/s12248-017-0057-9 28233244 · DOI
  75. [76]Baek SE Lee KH Park YS Oh D-K Oh S Kim K-S RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo J Control Release 2014 196 234 242 10.1016/j.jconrel.2014.10.018 25450401 · DOI
  76. [77]Yang H Liu H Kang H Tan W Engineering target-responsive hydrogels based on aptamer−target interactions J Am Chem Soc 2008 130 6320 6321 10.1021/ja801339w 18444626 PMC2757630 · DOI
  77. [78]Famulok M Hartig JS Mayer G Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy Chem Rev 2007 107 3715 3743 10.1021/cr0306743 17715981 · DOI
  78. [79]Wang T Luo Y Lv H Wang J Zhang Y Pei R Aptamer-based erythrocyte-derived mimic vesicles loaded with siRNA and doxorubicin for the targeted treatment of multidrug-resistant tumors ACS Appl Mater Interfaces 2019 11 45455 45466 10.1021/acsami.9b16637 31718159 · DOI
  79. [80]Karim R Somani S Al Robaian M Mullin M Amor R McConnell G Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol J Control Release 2017 246 79 87 10.1016/j.jconrel.2016.12.014 27993600 · DOI
  80. [81]Shi X Cheng Q Hou T Han M Smbatyan G Lang JE Genetically engineered cell-derived nanoparticles for targeted breast cancer immunotherapy Mol Ther 2020 28 536 547 10.1016/j.ymthe.2019.11.020 31843452 PMC7001084 · DOI
  81. [82]Cheng Q Shi X Han M Smbatyan G Lenz H-J Zhang Y Reprogramming exosomes as nanoscale controllers of cellular immunity J Am Chem Soc 2018 140 16413 16417 10.1021/jacs.8b10047 30452238 PMC6469991 · DOI
  82. [84]Li B Wei J Di C Lu Z Qi F Zhang Y Molecularly engineered truncated tissue factor with therapeutic aptamers for tumor-targeted delivery and vascular infarction Acta Pharmaceutica Sinica B 2021 11 2059 2069 10.1016/j.apsb.2020.11.014 34386338 PMC8343113 · DOI
  83. [85]Hosseini NF Amini R Ramezani M Saidijam M Hashemi SM Najafi R AS1411 aptamer-functionalized exosomes in the targeted delivery of doxorubicin in fighting colorectal cancer Biomed Pharmacother 2022 155 113690 10.1016/j.biopha.2022.113690 36099793 · DOI
  84. [86]Zou J Shi M Liu X Jin C Xing X Qiu L Aptamer-functionalized exosomes: elucidating the cellular uptake mechanism and the potential for cancer-targeted chemotherapy Anal Chem 2019 91 2425 2430 10.1021/acs.analchem.8b05204 30620179 PMC6662586 · DOI
  85. [87]Sato YT Umezaki K Sawada S Mukai S Sasaki Y Harada N Engineering hybrid exosomes by membrane fusion with liposomes Sci Rep 2016 6 21933 10.1038/srep21933 26911358 PMC4766490 · DOI · Paper page
  86. [88]Lv Q Cheng L Lu Y Zhang X Wang Y Deng J Thermosensitive exosome-liposome hybrid nanoparticle-mediated chemoimmunotherapy for improved treatment of metastatic peritoneal cancer Adv Sci 2020 7 2000515 10.1002/advs.202000515 PMC7509655 32999828 · DOI
  87. [89]Piffoux M Silva AKA Wilhelm C Gazeau F Tareste D Modification of extracellular vesicles by fusion with liposomes for the design of personalized biogenic drug delivery systems ACS Nano 2018 12 6830 6842 10.1021/acsnano.8b02053 29975503 · DOI
  88. [90]Lin Y Wu J Gu W Huang Y Tong Z Huang L Exosome-liposome hybrid nanoparticles deliver CRISPR/Cas9 system in MSCs Adv Sci 2018 5 1700611 10.1002/advs.201700611 PMC5908366 29721412 · DOI · Paper page
  89. [91]Li L He D Guo Q Zhang Z Ru D Wang L Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer J Nanobiotechnol 2022 20 50 10.1186/s12951-022-01264-5 PMC8787930 35078498 · DOI
  90. [92]Sun L Fan M Huang D Li B Xu R Gao F Clodronate-loaded liposomal and fibroblast-derived exosomal hybrid system for enhanced drug delivery to pulmonary fibrosis Biomaterials 2021 271 120761 10.1016/j.biomaterials.2021.120761 33774524 · DOI
  91. [93]Cheng L Zhang X Tang J Lv Q Liu J Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy Biomaterials 2021 275 120964 10.1016/j.biomaterials.2021.120964 34147721 · DOI
  92. [94]Buschmann D Mussack V Byrd JB Separation, characterization, and standardization of extracellular vesicles for drug delivery applications Adv Drug Deliv Rev 2021 174 348 368 10.1016/j.addr.2021.04.027 33964356 PMC8217305 · DOI
  93. [95]Son K Ueda M Taguchi K Maruyama T Takeoka S Ito Y Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes J Control Release 2020 322 209 216 10.1016/j.jconrel.2020.03.022 32194174 · DOI
  94. [96]Thorsteinsson K Olsén E Schmidt E Pace H Bally M FRET-based assay for the quantification of extracellular vesicles and other vesicles of complex composition Anal Chem 2020 92 15336 15343 10.1021/acs.analchem.0c02271 33179908 PMC7735656 · DOI
  95. [97]Tang T-T Lv L-L Lan H-Y Liu B-C Extracellular vesicles: opportunities and challenges for the treatment of renal diseases Front Physiol 2019 10 226 10.3389/fphys.2019.00226 30941051 PMC6433711 · DOI
  96. [98]Orefice NS Development of new strategies using extracellular vesicles loaded with exogenous nucleic acid Pharmaceutics 2020 12 705 10.3390/pharmaceutics12080705 32722622 PMC7464422 · DOI
  97. [99]Wang C, Yan A, Wang H, Su Y, Li D. DNA‐mediated membrane fusion and its biological applications: sensing, reaction control and drug delivery. Analysis & Sensing. 2022. 10.1002/anse.202200024 · DOI
  98. [100]Mora NL Boyle AL van Kolck BJ Rossen A Pokorná Š Koukalová A Controlled peptide-mediated vesicle fusion assessed by simultaneous dual-colour time-lapsed fluorescence microscopy Sci Rep 2020 10 3087 10.1038/s41598-020-59926-z 32080270 PMC7033240 · DOI
  99. [101]Jing K Guo Y Ng I-S Antigen-43-mediated surface display revealed in Escherichia coli by different fusion sites and proteins Bioresour Bioprocess 2019 6 14 10.1186/s40643-019-0248-6 · DOI
  100. [102]Han M-J Lee SH An efficient bacterial surface display system based on a novel outer membrane anchoring element from the Escherichia coli protein YiaT FEMS Microbiol Lett 2015 362 1 7 10.1093/femsle/fnu002 25790485 · DOI
  101. [103]Green ER Mecsas J Bacterial secretion systems: an overview Microbiol Spectr 2016 4 10 10.1128/microbiolspec.VMBF-0012-2015 PMC4804464 26999395 · DOI
  102. [104]Vo JL Martínez Ortiz GC Subedi P Keerthikumar S Mathivanan S Paxman JJ Autotransporter adhesins in Escherichia coli pathogenesis Proteomics 2017 17 1600431 10.1002/pmic.201600431 28665015 · DOI
  103. [105]Hörnström D Larsson G van Maris AJA Gustavsson M Molecular optimization of autotransporter-based tyrosinase surface display Biochim Biophys Acta Biomembr 2019 1861 486 494 10.1016/j.bbamem.2018.11.012 30521785 · DOI
  104. [106]van den Berg van Saparoea HB, Houben D, de Jonge MI, Jong WSP, Luirink J. Display of Recombinant Proteins on Bacterial Outer Membrane Vesicles by Using Protein Ligation. Drake HL, editor. Appl Environ Microbiol. 2018;84: e02567–17. PMC5881043 29439988
  105. [107]Lång H Outer membrane proteins as surface display systems Int J Med Microbiol 2000 290 579 585 10.1016/S1438-4221(00)80004-1 11200539 · DOI
  106. [108]Hui C Guo Y Zhang W Gao C Yang X Chen Y Surface display of PbrR on Escherichia coli and evaluation of the bioavailability of lead associated with engineered cells in mice Sci Rep 2018 8 5685 10.1038/s41598-018-24134-3 29632327 PMC5890273 · DOI
  107. [109]Cole GB Bateman TJ Moraes TF The surface lipoproteins of gram-negative bacteria: Protectors and foragers in harsh environments J Biol Chem 2021 296 100147 10.1074/jbc.REV120.008745 33277359 PMC7857515 · DOI
  108. [110]Huynh MS Hooda Y Li YR Jagielnicki M Lai CC-L Moraes TF Reconstitution of surface lipoprotein translocation through the Slam translocon Life 2022 11 e72822 PMC9090332 35475756
  109. [111]Cheng K Zhao R Li Y Qi Y Wang Y Zhang Y Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology Nat Commun 2021 12 2041 10.1038/s41467-021-22308-8 33824314 PMC8024398 · DOI · Paper page
  110. [112]Sepahdar Z Miroliaei M Bouzari S Khalaj V Salimi M Surface engineering of escherichia coli–derived omvs as promising nano-carriers to target EGFR-overexpressing breast cancer cells Front Pharmacol 2021 12 719289 10.3389/fphar.2021.719289 34867325 PMC8638777 · DOI
  111. [113]Hatlem D Trunk T Linke D Leo JC Catching a SPY: using the SpyCatcher-SpyTag and related systems for labeling and localizing bacterial proteins IJMS 2019 20 2129 10.3390/ijms20092129 31052154 PMC6539128 · DOI
  112. [114]Jiang L, Driedonks TAP, Jong WSP, Dhakal S, Bart van den Berg van Saparoea H, Sitaras I, et al. A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants. J of Extracellular Vesicle. 2022. 10.1002/jev2.12192 PMC8920961 35289114 · DOI
  113. [115]Weyant KB Oloyede A Pal S Liao J Jesus MR-D Jaroentomeechai T A modular vaccine platform enabled by decoration of bacterial outer membrane vesicles with biotinylated antigens Nat Commun 2023 14 464 10.1038/s41467-023-36101-2 36709333 PMC9883832 · DOI
  114. [116]García-Manrique P Matos M Gutiérrez G Pazos C Blanco-López MC Therapeutic biomaterials based on extracellular vesicles: classification of bio-engineering and mimetic preparation routes Journal of Extracellular Vesicles 2018 7 1422676 10.1080/20013078.2017.1422676 29372017 PMC5774402 · DOI
  115. [117]Syromiatnikova V Prokopeva A Gomzikova M Methods of the large-scale production of extracellular vesicles IJMS 2022 23 10522 10.3390/ijms231810522 36142433 PMC9506336 · DOI
  116. [118]Sun L Wang H Zhu X Wu P Chen W Zou P Serum deprivation elevates the levels of microvesicles with different size distributions and selectively enriched proteins in human myeloma cells in vitro Acta Pharmacol Sin 2014 35 381 393 10.1038/aps.2013.166 24374813 PMC4647891 · DOI
  117. [119]Gong C Zhang X Shi M Li F Wang S Wang Y Tumor exosomes reprogrammed by low ph are efficient targeting vehicles for smart drug delivery and personalized therapy against their homologous tumor Adv Sci 2021 8 2002787 10.1002/advs.202002787 PMC8132050 34026432 · DOI
  118. [120]Kurbangaleeva SV Syromiatnikova VY Prokopeva AE Rogov AM Khannanov AA Rizvanov AA Increased yield of extracellular vesicles after cytochalasin B treatment and vortexing CIMB 2023 45 2431 2443 10.3390/cimb45030158 36975528 PMC10047179 · DOI
  119. [121]Nair A Bu J Rawding PA Do SC Li H Hong S Cytochalasin B treatment and osmotic pressure enhance the production of extracellular vesicles (EVs) with improved drug loading capacity Nanomaterials 2021 12 3 10.3390/nano12010003 35009953 PMC8746776 · DOI
  120. [122]Taylor J Azimi I Monteith G Bebawy M Ca 2+ mediates extracellular vesicle biogenesis through alternate pathways in malignancy J Extracell Vesicle 2020 9 1734326 10.1080/20013078.2020.1734326 PMC7067202 32194926 · DOI
  121. [123]Kang H Bae Y Kwon Y Kim S Park J Extracellular vesicles generated using bioreactors and their therapeutic effect on the acute kidney injury model Adv Healthcare Materials 2022 11 2101606 10.1002/adhm.202101606 34773445 · DOI
  122. [124]Grangier A Branchu J Volatron J Piffoux M Gazeau F Wilhelm C Technological advances towards extracellular vesicles mass production Adv Drug Deliv Rev 2021 176 113843 10.1016/j.addr.2021.113843 34147532 · DOI
  123. [125]Clos-Sansalvador M Monguió-Tortajada M Roura S Franquesa M Borràs FE Commonly used methods for extracellular vesicles’ enrichment: Implications in downstream analyses and use Eur J Cell Biol 2022 101 151227 10.1016/j.ejcb.2022.151227 35460958 · DOI
  124. [126]Paganini C Capasso Palmiero U Pocsfalvi G Touzet N Bongiovanni A Arosio P Scalable production and isolation of extracellular vesicles: available sources and lessons from current industrial bioprocesses Biotechnol J 2019 14 1800528 10.1002/biot.201800528 31140717 · DOI
  125. [127]Luo L Wu Z Wang Y Li H Regulating the production and biological function of small extracellular vesicles: current strategies, applications and prospects J Nanobiotechnol 2021 19 422 10.1186/s12951-021-01171-1 PMC8670141 34906146 · DOI
  126. [128]Tian Y Gong M Hu Y Liu H Zhang W Zhang M Quality and efficiency assessment of six extracellular vesicle isolation methods by nano-flow cytometry J Extracell Vesicles 2020 9 1697028 10.1080/20013078.2019.1697028 31839906 PMC6896440 · DOI · Paper page
  127. [129]Chen C Sun M Wang J Su L Lin J Yan X Active cargo loading into extracellular vesicles: Highlights the heterogeneous encapsulation behaviour J Extracell Vesicles 2021 10.1002/jev2.12163 34719860 PMC8558234 · DOI
  128. [130]Jang Y Chung HJ Hong JW Yun C-W Chung H Absorption mechanism of DHP107, an oral paclitaxel formulation that forms a hydrated lipidic sponge phase Acta Pharmacol Sin 2017 38 133 145 10.1038/aps.2016.105 27867185 PMC5220538 · DOI
  129. [131]Li S Lin Z Jiang X Yu X Exosomal cargo-loading and synthetic exosome-mimics as potential therapeutic tools Acta Pharmacol Sin 2018 39 542 551 10.1038/aps.2017.178 29417947 PMC5888690 · DOI
  130. [132]Golubovic A Tsai S Li B Bioinspired lipid nanocarriers for RNA delivery ACS Bio Med Chem Au 2023 3 114 136 10.1021/acsbiomedchemau.2c00073 37101812 PMC10125326 · DOI
  131. [133]Bost JP Barriga H Holme MN Gallud A Maugeri M Gupta D Delivery of oligonucleotide therapeutics: chemical modifications, lipid nanoparticles, and extracellular vesicles ACS Nano 2021 15 13993 14021 10.1021/acsnano.1c05099 34505766 PMC8482762 · DOI
  132. [134]Walker S Busatto S Pham A Tian M Suh A Carson K Extracellular vesicle-based drug delivery systems for cancer treatment Theranostics 2019 9 8001 8017 10.7150/thno.37097 31754377 PMC6857056 · DOI
  133. [135]Liu S Wu X Chandra S Lyon C Ning B Jiang L Extracellular vesicles: Emerging tools as therapeutic agent carriers Acta Pharmaceutica Sinica B 2022 12 3822 3842 10.1016/j.apsb.2022.05.002 36213541 PMC9532556 · DOI
  134. [136]Ashkar A Sosnik A Davidovich-Pinhas M Structured edible lipid-based particle systems for oral drug-delivery Biotechnol Adv 2022 54 107789 10.1016/j.biotechadv.2021.107789 34186162 · DOI
  135. [137]Song H Chen X Hao Y Wang J Xie Q Wang X Nanoengineering facilitating the target mission: targeted extracellular vesicles delivery systems design J Nanobiotechnol 2022 20 431 10.1186/s12951-022-01638-9 PMC9524104 36175866 · DOI
  136. [138]Luan X Sansanaphongpricha K Myers I Chen H Yuan H Sun D Engineering exosomes as refined biological nanoplatforms for drug delivery Acta Pharmacol Sin 2017 38 754 763 10.1038/aps.2017.12 28392567 PMC5520184 · DOI
  137. [139]Tenchov R Bird R Curtze AE Zhou Q Lipid nanoparticles─from liposomes to mrna vaccine delivery, a landscape of research diversity and advancement ACS Nano 2021 15 16982 17015 10.1021/acsnano.1c04996 34181394 · DOI · Paper page
  138. [140]Nazarova A Yakimova L Filimonova D Stoikov I Surfactant effect on the physicochemical characteristics of solid lipid nanoparticles based on pillar[5]arenes IJMS 2022 23 779 10.3390/ijms23020779 35054962 PMC8775580 · DOI
  139. [141]Baldim I Rosa DM Souza CRF Da Ana R Durazzo A Lucarini M Factors affecting the retention efficiency and physicochemical properties of spray dried lipid nanoparticles loaded with lippia sidoides essential oil Biomolecules 2020 10 693 10.3390/biom10050693 32365717 PMC7277518 · DOI
  140. [142]Gelibter S Marostica G Mandelli A Siciliani S Podini P Finardi A The impact of storage on extracellular vesicles: a systematic study J Extracell Vesicle 2022 11 e12162 10.1002/jev2.12162 PMC8804350 35102719 · DOI
  141. [143]Nakhaei P Margiana R Bokov DO Abdelbasset WK Jadidi Kouhbanani MA Varma RS Liposomes: structure, biomedical applications, and stability parameters with emphasis on cholesterol Front Bioeng Biotechnol 2021 9 705886 10.3389/fbioe.2021.705886 34568298 PMC8459376 · DOI
  142. [144]Görgens A Corso G Hagey DW Jawad Wiklander R Gustafsson MO Felldin U Identification of storage conditions stabilizing extracellular vesicles preparations J Extracell Vesicle 2022 10.1002/jev2.12238 PMC9206228 35716060 · DOI
  143. [145]Nordin JZ Lee Y Vader P Mäger I Johansson HJ Heusermann W Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties Nanomedicine 2015 11 879 883 10.1016/j.nano.2015.01.003 25659648 · DOI
  144. [146]van de Wakker SI van Oudheusden J Mol EA Roefs MT Zheng W Görgens A Influence of short term storage conditions, concentration methods and excipients on extracellular vesicle recovery and function Eur J Pharm Biopharm 2022 170 59 69 10.1016/j.ejpb.2021.11.012 34864197 · DOI
  145. [147]Mitragotri S Lammers T Bae YH Schwendeman S De Smedt S Leroux J-C Drug delivery research for the future: expanding the nano horizons and beyond J Control Release 2017 246 183 184 10.1016/j.jconrel.2017.01.011 28110715 · DOI
  146. [148]Waheed S Li Z Zhang F Chiarini A Armato U Wu J Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery J Nanobiotechnol 2022 20 395 10.1186/s12951-022-01605-4 PMC9428887 36045386 · DOI · Paper page
  147. [149]Veronese FM Pasut G PEGylation, successful approach to drug delivery Drug Discovery Today 2005 10 1451 1458 10.1016/S1359-6446(05)03575-0 16243265 · DOI
  148. [150]Mohamed M Abu Lila AS Shimizu T Alaaeldin E Hussein A Sarhan HA PEGylated liposomes: immunological responses Sci Technol Adv Mater 2019 20 710 724 10.1080/14686996.2019.1627174 31275462 PMC6598536 · DOI
  149. [151]Liu M Chu Y Liu H Su Y Zhang Q Jiao J Accelerated blood clearance of nanoemulsions modified with PEG-cholesterol and PEG-phospholipid derivatives in rats: the effect of PEG-lipid linkages and PEG molecular weights Mol Pharmaceutics 2020 17 1059 1070 10.1021/acs.molpharmaceut.9b00770 31860321 · DOI
  150. [152]Fang RH Hu C-MJ Zhang L Nanoparticles disguised as red blood cells to evade the immune system Expert Opin Biol Ther 2012 12 385 389 10.1517/14712598.2012.661710 22332936 · DOI
  151. [153]Pisano C Cecere SC Di Napoli M Cavaliere C Tambaro R Facchini G Clinical trials with pegylated liposomal doxorubicin in the treatment of ovarian cancer J Drug Delivery 2013 2013 1 12 10.1155/2013/898146 PMC3612436 23577259 · DOI
  152. [154]Miao G He Y Lai K Zhao Y He P Tan G Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients J Control Release 2023 363 12 26 10.1016/j.jconrel.2023.09.003 37717659 · DOI
  153. [155]Elsharkasy OM Nordin JZ Hagey DW De Jong OG Schiffelers RM Andaloussi SE Extracellular vesicles as drug delivery systems: why and how? Adv Drug Deliv Rev 2020 159 332 343 10.1016/j.addr.2020.04.004 32305351 · DOI
  154. [156]Takahashi Y Nishikawa M Shinotsuka H Matsui Y Ohara S Imai T Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection J Biotechnol 2013 165 77 84 10.1016/j.jbiotec.2013.03.013 23562828 · DOI
  155. [157]Smith ZJ Lee C Rojalin T Carney RP Hazari S Knudson A Single exosome study reveals subpopulations distributed among cell lines with variability related to membrane content J Extracellular Vesicle 2015 4 28533 10.3402/jev.v4.28533 PMC4673914 26649679 · DOI
  156. [158]Cully M Exosome-based candidates move into the clinic Nat Rev Drug Discov 2021 20 6 7 10.1038/d41573-020-00220-y 33311580 · DOI
  157. [159]Lewis ND Sia CL Kirwin K Haupt S Mahimkar G Zi T Exosome surface display of IL12 results in tumor-retained pharmacology with superior potency and limited systemic exposure compared with recombinant IL12 Mol Cancer Ther 2021 20 523 534 10.1158/1535-7163.MCT-20-0484 33443094 · DOI
  158. [160]Mitchell J Scarisbrick J De Francesco I Cowan R McKay P Osborne W Abstract CT114: Randomized placebo-controlled Phase 1 trial in healthy volunteers investigating safety, PK and PD of exoIL-12 - a novel engineered exosome therapeutic candidate Cancer Res 2021 10.1158/1538-7445.AM2021-CT114 · DOI
  159. [161]Osteikoetxea X Silva A Lázaro-Ibáñez E Salmond N Shatnyeva O Stein J Engineered Cas9 extracellular vesicles as a novel gene editing tool J Extracell Vesicle 2022 11 e12225 10.1002/jev2.12225 PMC9117459 35585651 · DOI
  160. [162]Saari H Turunen T Lõhmus A Turunen M Jalasvuori M Butcher SJ Extracellular vesicles provide a capsid-free vector for oncolytic adenoviral DNA delivery J Extracell Vesicle 2020 9 1747206 10.1080/20013078.2020.1747206 PMC7178890 32363012 · DOI
  161. [163]Lennaárd AJ Mamand DR Wiklander RJ El Andaloussi S Wiklander OPB Optimised electroporation for loading of extracellular vesicles with doxorubicin Pharmaceutics 2021 14 38 10.3390/pharmaceutics14010038 35056933 PMC8780628 · DOI
  162. [164]Schwendener RA Liposomes as vaccine delivery systems: a review of the recent advances Therapeutic Adv Vaccines 2014 2 159 182 10.1177/2051013614541440 PMC4212474 25364509 · DOI
  163. [165]Sekhon SS Shin W Kim SY Jeong D Choi W Choi B Cyclophilin A-mediated mitigation of coronavirus SARS-CoV -2 Bioeng Transla Med 2023 10.1002/btm2.10436 PMC9874840 36712291 · DOI
  164. [166]Berumen Sánchez G Bunn KE Pua HH Rafat M Extracellular vesicles: mediators of intercellular communication in tissue injury and disease Cell Commun Signal 2021 19 104 10.1186/s12964-021-00787-y 34656117 PMC8520651 · DOI
  165. [167]Nagelkerke A Ojansivu M van der Koog L Whittaker TE Cunnane EM Silva AM Extracellular vesicles for tissue repair and regeneration: evidence, challenges and opportunities Adv Drug Deliv Rev 2021 175 113775 10.1016/j.addr.2021.04.013 33872693 · DOI
  166. [168]Tan SSH Tjio CKE Wong JRY Wong KL Chew JRJ Hui JHP Mesenchymal stem cell exosomes for cartilage regeneration: a systematic review of preclinical In Vivo studies Tissue Eng Part B Rev 2021 27 1 13 10.1089/ten.teb.2019.0326 32159464 · DOI
  167. [169]Grieco GE Fignani D Formichi C Nigi L Licata G Maccora C Extracellular vesicles in immune system regulation and type 1 diabetes: cell-to-cell communication mediators, disease biomarkers, and promising therapeutic tools Front Immunol 2021 12 682948 10.3389/fimmu.2021.682948 34177928 PMC8219977 · DOI
  168. [170]Garcia-Contreras M Shah SH Tamayo A Robbins PD Golberg RB Mendez AJ Plasma-derived exosome characterization reveals a distinct microRNA signature in long duration Type 1 diabetes Sci Rep 2017 7 5998 10.1038/s41598-017-05787-y 28729721 PMC5519761 · DOI
  169. [171]Xu S Cheuk YC Jia Y Chen T Chen J Luo Y Bone marrow mesenchymal stem cell-derived exosomal miR-21a-5p alleviates renal fibrosis by attenuating glycolysis by targeting PFKM Cell Death Dis 2022 13 876 10.1038/s41419-022-05305-7 36253358 PMC9576726 · DOI
  170. [172]Chavda VP Vihol D Mehta B Shah D Patel M Vora LK Phytochemical-loaded liposomes for anticancer therapy: an updated review Nanomedicine 2022 17 547 568 10.2217/nnm-2021-0463 35259920 · DOI
  171. [174]Shi X Sun J Li H Lin H Xie W Li J Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate cancer Prostate 2020 80 811 823 10.1002/pros.23996 32427375 · DOI
  172. [175]Santos P Almeida F Exosome-based vaccines: history, current state, and clinical trials Front Immunol 2021 12 711565 10.3389/fimmu.2021.711565 34335627 PMC8317489 · DOI
  173. [176]Leiva-Sabadini C Alvarez S Barrera NP Schuh CM Aguayo S Antibacterial effect of honey-derived exosomes containing antimicrobial peptides against oral streptococci IJN 2021 16 4891 4900 10.2147/IJN.S315040 34321877 PMC8312616 · DOI
  174. [177]Ahn G Shin W-R Lee S Yoon H-W Choi J-W Kim Y-H Bovine colostrum exosomes are a promising natural bacteriostatic agent against Staphylococcus aureus ACS Infect Dis 2023 9 993 1003 10.1021/acsinfecdis.3c00022 36994948 · DOI
  175. [178]Sao R Vaish R Sinha N Multifunctional drug delivery systems using inorganic nanomaterials: a review J Nanosci Nanotechnol 2015 15 1960 1972 10.1166/jnn.2015.9761 26413609 · DOI
  176. [179]Zare H Ahmadi S Ghasemi A Ghanbari M Rabiee N Bagherzadeh M Carbon nanotubes: smart drug/gene delivery carriers IJN 2021 16 1681 1706 10.2147/IJN.S299448 33688185 PMC7936533 · DOI
  177. [180]Hu M Ge X Chen X Mao W Qian X Yuan W-E Micro/nanorobot: a promising targeted drug delivery system Pharmaceutics 2020 12 665 10.3390/pharmaceutics12070665 32679772 PMC7407549 · DOI

Cited by

Sorted by citations

Authors
Marquez, C. A., Oh, C.-I., Ahn, G., Shin, W.-R., Kim, Y.-H., & Ahn, J.-Y.
Affiliations
Chungbuk National University (KR)
Corresponding author
  • Kim, Yang-Hoon
  • Ahn, Ji-Young
ORCID
Venue
Journal of Nanobiotechnology
Publisher
Springer Science and Business Media LLC
Published
2024-01-03
Volume
22
Issue
1
Pages
6-6
ISSN
1477-3155 (ISSN-L)
DOI
10.1186/s12951-023-02275-6
PMC
PMC10763086
OpenAlex
W4390545796
Cited by
37
References
3
Citations by year
2026: 14 · 2025: 14 · 2024: 9
FWCI
1.05
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Nanobiotechnology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Research Foundation of Korea (2020R1A6A1A06046235)
  • Commercializations Promotion Agency for R and D Outcomes (1711173792)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords
targeted drug delivery, lipid vesicles, target specificity, nanomedicine
MeSH terms
Extracellular Vesicles, Drug Delivery Systems, Nanotechnology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review